- Office Hour : 08:00am - 6:00pm
Our Story
Built for Partnerships. Driven by Purpose. Advancing Health Science.
Cohance Lifesciences is not just a brand—it’s a culmination of vision, scientific ambition, and purposeful integration. Our story began with a series of intentional moves, starting with the acquisition of RA Chem Pharma.
Over time, a deliberate series of mergers and acquisitions—including ZCL Chemicals, Avra Laboratories, Suven Pharmaceuticals, Sapala Organics, and NJ Bio—brought together differentiated capabilities in Pharma CDMO, APIs, Specialty Chemicals, Formulations, and next-gen platforms like ADCs and Oligonucleotides.
Explore Our Journey
2020
The journey begins with RA Chem Pharma
The foundation was laid with the inclusion of RA Chem Pharma, known for its strong footprint in APIs, intermediates, and finished dosage formulations…setting the tone for a platform focused on quality and scientific depth.
2021
ZCL Chemicals adds strength in complex chemistry
With the addition of ZCL Chemicals, the platform expanded its capability in complex intermediates, enhancing its ability to serve global pharmaceutical innovators.
2022
Avra Laboratories brings niche capabilities
The journey progressed with Avra, bringing expertise in high-complexity chemistry and ADC payloads – positioning the platform to support next-generation therapeutics.
2023
Suven Pharmaceuticals merges with Cohance
Suven Pharmaceuticals, with its rich heritage in CRAMS and custom synthesis, joined hands with the growing platform. This marked a pivotal point where the vision of Cohance – a differentiated, technology-led CDMO platform – began to take shape.
2024
Expanding into next-gen therapeutic platforms
While the Cohance–Suven integration was underway, the platform advanced further with Sapala Organics (bringing oligonucleotide capabilities) and NJ Bio (offering end-to-end integrated ADC services), broadening scientific reach in novel modalities.
2025 & beyond
Cohance Lifesciences Limited…a unified global CDMO platform
With the integration of capabilities from all its constituents, the combined entity moves forward as Cohance Lifesciences Limited – a fully integrated, innovation-led partner to global pharma companies, spanning CDMO, APIs, specialty chemicals, and FDF.
The name Cohance reflects our foundational belief in Collaboration and Enhancement. This inherent belief guides how we show up: as steadfast allies to our partners, with a drive to go beyond the expected.
From development to commercialization, we bring together expert teams and technologies with a singular purpose: advancing solutions for a healthier world through integrated chemistry and technology capabilities.
With each milestone, we’ve strengthened our standing as a distinctive and reliable partner to life sciences innovators who are reimagining healthcare in meaningful ways.
Today, as a global CDMO with state-of-the-art facilities across India and the U.S., we remain true to our promise:
Collaborate. Enhance. Deliver.